Altered placental immune cell composition and gene expression with isolated fetal spina bifida

Marina White 1, Hasan Abdo 1, David Grynspan 2,3, Tim Van Mieghem 4, *Kristin L Connor 1

1 Department of Health Sciences, Carleton University, Ottawa, ON K1S 5B6, Canada;
2 Vernon Jubilee Hospital, Vernon, BC V1T 5L2, Canada;
3 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada;
4 Department of Obstetrics and Gynecology, Sinai Health System, Toronto, ON M5G 1X5, Canada

* Correspondence:
Dr. Kristin Connor
Department of Health Sciences, Carleton University, Ottawa, Ontario, Canada, K1S5B6
E: kristin.connor@carleton.ca, Tel.: +1 613-520-2600 ext. 4202

Abstract

Problem: Maternal B vitamin deficiency increases the risk of fetal spina bifida (SB) and placental maldevelopment. It is unclear whether placental processes involving folate are altered in fetuses with SB in a contemporary cohort. We hypothesised that fetal SB would associate with reduced expression of key folate transporters (folate receptor-α [FRα], proton coupled folate receptor [PCFT], and reduced folate carrier [RFC]), and an increase in Hofbauer cell (HBC) abundance and folate receptor-β (FRβ) expression by HBCs.

Method of Study: FRα, PCFT, and RFC protein localisation and expression (immunohistochemistry) and HBC phenotypes (RNA in situ hybridization) were assessed in placentae from fetuses with SB (cases; n=12) and with no congenital anomalies (controls; n=22).

Results: Cases (vs. gestational age [GA]-matched controls) had a higher proportion of placental villous cells that were HBCs (6.9% vs. 2.4%, p=0.0001) and higher average FRβ expression by HBCs (3.2 mRNA molecules per HBC vs. 2.3, p=0.03). HBCs in cases were largely polarised to a regulatory (M2) phenotype (median 92.1% of HBCs). In sex-stratified analyses, male, but not female, cases had higher HBC levels and FRβ expression by HBCs than GA-matched controls. There were no differences between groups in the total percent of syncytium and stromal cells that were positive for FRα, PCFT, or RFC protein immunolabelling.

Conclusions: HBC abundance and FRβ expression by HBCs are increased in placenta of fetuses with isolated SB, suggesting immune-mediated dysregulation in placental development and function, and could contribute to SB-associated comorbidities, such as poor fetal growth.

Keywords: Neural tube defects, spina bifida, placenta, folate, Hofbauer cells

Introduction

Maternal periconceptional deficiencies of folate and folate metabolism co-factors are known to increase the risk of fetal neural tube defects (NTDs)1-3. Around half of NTDs are estimated to be responsive to folic acid14,15. However, folates are essential throughout pregnancy, well-beyond the period of neural tube closure, to support fetalplacental growth and placental function5. It is unclear whether placenta from fetuses with NTDs may be at increased risk of dysfunction in processes involving folate, and whether these disruptions may contribute to the poor growth6,7 and early birth8,9 experienced by these fetuses10,12.

Hofbauer cells (HBCs) are placental macrophages of fetal origin that highly express folate receptor-β (FRβ), one of the major placental folate transporters13-15. HBCs favour polarisation towards a regulatory (M2) phenotype16, and as a result, play a critical role in the regulation of placental angiogenesis, immune function, and inflammation15. Although HBCs are detectable as early as 18 days post-fertilization14,15, HBC ontogeny across gestation is not well defined. Importantly, as HBCs express FRβ, it is possible that beginning early in pregnancy, HBC level and function could be sensitive to changes in local folate bioavailability and/or metabolism. In assessments of placental histopathology from both historical (pre-folic acid fortification/supplementation) and contemporary cohorts12,17, we have shown that fetuses with NTDs have increased HBC abundance. However, how HBC phenotype may be altered in fetuses with NTDs remains unknown. It is plausible that a uterine environment permissive of NTDs may influence HBC phenotype and function, and that these changes could contribute to placental villous maldevelopment, as observed in these cases12,17.

Folates are also actively transported to the fetus to support fetal growth and development through transmembrane transporters18. Folate uptake and transport across the placental syncytium is coordinated by folate receptor-α (FRα), proton coupled folate receptor (PCFT/heme carrier protein 1 [HCP1]), and reduced folate carrier (RFC)14,18,19. Reduced activity in these transporters is associated with suboptimal fetal outcomes, such as intrauterine growth restriction20. Conversely, in fetuses with NTDs, an adaptive upregulation of placental FRα and RFC expression has been observed in response to low folate bioavailability21. However, it remains unclear if placental folate transport in fetuses with NTDs may be altered in regions with a low burden of folate deficiency, where maternal folate levels are likely adequate, and whether compromised placental folate transport may relate to the poor growth outcomes often experienced by these fetuses10,12.
Here we aimed to better understand whether, and how, HBC phenotype and placental folate transport were altered in fetuses with isolated spina bifida (SB; the most common NTD) compared to placentae from fetuses with no congenital anomalies. We also aimed to understand whether changes in placental HBC phenotype and folate transport differed based on placental sex. We hypothesised that cases would have a higher number of HBCs, and that HBCs would have increased FRβ expression and adopt a more activated (M1-like) phenotype. We also hypothesised that cases would have reduced expression of folate transporters, increasing the risk of poor fetal growth. Lastly, to understand the mechanisms that may underly changes in placental phenotype, we explored relationships between key maternal and infant characteristics, HBC phenotype, and placental folate transport.

Methods

Ethics

This study was approved by the Carleton University Research Ethics Board (108884 and 106932) and the Mount Sinai Hospital Research Ethics Board (17-0028-E and 17-0186-E).

Population and study design

This study population has been previously described22. Pregnant people carrying a fetus were recruited at approximately 25 weeks' gestation at Mount Sinai Hospital, Toronto. Controls were singleton pregnancies with no known fetal anomalies. At recruitment, maternal clinical data, medical history, and dietary recall questionnaire data were collected, and data on pregnancy and birth outcomes were collected at delivery. A second group control matched to cases for gestational age (GA) at delivery was also identified (preterm controls [hereon referred to as PT controls]) at the same site. PT controls were singleton pregnancies with no known fetal anomalies or maternal pregnancy complications22, and were matched 1:1 with cases for GA at delivery and maternal pre-pregnancy body mass index (BMI)23.

Maternal clinical, demographic, and dietary characteristics

Maternal clinical data and medical history, and dietary recall questionnaire data (Automated Self-Administered 24-hour Recall™, specific to the Canadian population [ASA24-Canada-2016]25) were collected at recruitment for cases and controls. The maternal dietary recall data have been previously reported in full22, and here, we analysed reported maternal intakes of folate and vitamins B6 and B12 as exposure variables of interest.

Infant birth outcomes

Data on pregnancy and infant birth outcomes have been previously reported for this cohort22. GA at delivery was calculated using maternal reports of last menstrual period to the nearest week. Birthweight z-scores adjusted for infant GA and sex were calculated using Canadian growth standards25.

Placental collection and processing

Sample collection

All placental samples were collected and processed by the Research Centre for Women's and Infants' Health BioBank immediately after delivery. Placental biopsies were collected from each of the four placental quadrants, at least 1.5 cm away from the centre and edge of the placental disk, fixed in paraformaldehyde and embedded in paraffin.

Immunohistochemistry

Immunohistochemistry (IHC) was used to assess placental folate transporter localisation and immunoreactive (ir) protein expression. Parafomaldehyde-fixed and paraffin-embedded (PFPE) placental samples were cut at 5 μm and placed on a slide warmer (Agar Scientific, Stansted, United Kingdom) for 30 minutes at 55°C. Placental sections were stained using rabbit polyclonal antibodies to visualize FRα (Anti-Folate Binding Protein/FBP; ab67422; 1:250), PCFT (Anti-HCPI/PCFT; Abcam ab25134; 1:100), and RFC (Anti-RFC; Abcam ab62302; 1:150). The slides were processed using a protocol previously described26, with a few modifications. In brief, after slides were deparaffinised in xylene and rehydrated in ethanol dilutions, a heat-induced antigen retrieval was performed in a microwave using a 10mM citric acid and sodium citrate (pH 6.0) solution. Slides were then washed with 1X phosphate-buffered saline (PBS), quenched using 3.0% hydrogen peroxide in 77% methanol to block endogenous peroxidase activity, and incubated with a protein-blocking solution (Agilent Dako, Santa Clara, USA) for one hour at room temperature to block non-specific binding. Slides were incubated overnight with each specific primary antibody at 4°C. A negative control was included in each run, for which the primary antibody was replaced with antibody diluent. Slides were incubated with a secondary antibody (1:200 goat biotinylated anti-rabbit antibody, BA-1000; Vector Labs, Burlingame, USA) and then streptavidin-horse radish peroxidase (1:2000 dilution in 1X PBS; Invitrogen, Carlsbad, USA) for one hour each at room temperature. Horse radish peroxidase enzymatic activity was detected through treatment with 3,3’ diaminobenzidine (DAB; Vectastain Elite ABC HRP Kit, Vector Laboratories, Brockville, Canada) for two minutes. Gill’s #1 haematoxylin (Sigma-Aldrich, Oakville, Canada) was used to counterstain the slides.

Whole placental sections from IHC analyses were scanned on the EVOS FL Auto 2 at 20X using the automatic function (Thermo Fisher Scientific, Waltham, MA, USA). The boundaries of the placental villous tissue on each slide were manually indicated within the software, and after scanning, unstitched image files were exported (range: 207-961 fields, depending on the size of placental tissue). A file list, where each file name corresponds to an image (field) captured, was generated for each antibody for each placenta. From this file list, 50 images from each placental sample were randomly selected for analyses using the ‘=rand(1)^’ and ‘=index(‘ functions in Excel.

Localisation and semi-quantitative expression of immunoreactive FRα, PCFT and RFC was assessed using QuPath (version 0.3.2)27, which has previously been used to analyse IHC images in placental tissue28,29. For each sample, colour deconvolution was performed (‘estimate stain vectors’ tool), the intensity of staining was evaluated (‘positive cell detection’ tool28), and the detection parameters were optimised (Supplementary Table S1 and Figure S1). The positive cells were classified as stained with low (threshold 1), medium (threshold 2), or high (threshold 3) intensity in alignment with visual assessments (Supplementary Table S1 and Figure S1). Percent syncytium and stromal cells stained overall, and at low, medium, and high thresholds, was quantified for each antibody.

RNA in situ hybridization

To evaluate the abundance, polarisation, and cellular origins of HBCs, as well as FRβ expression by HBCs, in situ hybridization (ISH) was performed using the RNAscope™ Multiplex Fluorescent v2 Assay (Cat. No. 323100; ACD-Bio). Following the manufacturer’s protocol30,31, PFPE placental samples were cut at 5 μm and placed on a slide warmer
Whole placental sections from ISH analyses were captured as Z-stack images at 20X on the Axio Scan Z1 Slide Scanner (ZEISS, Oberkochen, Germany). Five fluorescent channels were used simultaneously: Alexa Fluor (AF) 488 (Opal 520/MRC1/CD260 probe), AF568 (Opal 570/VIM probe), AF594 (Opal 620/FRβ probe), AF647 (Opal 690/CD80 probe), and a 405 nm diode laser for DAPI. ZEN lite (version 3.4) was used to process the images (CZI files). Following the calculation of average intensity projections for each pixel (orthogonal projection), linear unmixing was performed using the reference spectra for each Opal fluorophore, and reference spectra for DAPI obtained from a negative control slide. High levels of red blood cell autofluorescence in the green channel (AF488) rendered any probe signal undetectable, and this channel (tagged with the MRC1/CD260 probe) was excluded from subsequent analyses.

Linearly unmixed images (as CZI files) were exported for subsequent analysis in QuPath (version 0.3.2)\textsuperscript{7}, to assess the localisation and expression of target probes. Unmixed CZI files were imported into QuPath (Bio-Formats). For all but one sample, 20 fields of view (1000 μm x 1000 μm squares) containing only placental villous tissue, and not decidua, were identified for analysis using the DAPI signal (with this channel (tagged with the VIM fluorophore, and reference spectra for DAPI obtained from a negative control slide). For one sample from the case group, the placental tissue section was small and only sufficient to capture 13 fields of view. The assay manufacturer’s technical note on using QuPath to analyze RNAscope™ images was followed to identify cells that expressed the target probes using single measurement classifiers within each of the cell’s boundaries\textsuperscript{32,36}.

The RNAScope™ signal is displayed as punctate dots, where each dot represents a single copy of an mRNA molecule for the target gene and larger dots or clusters may indicate the presence of multiple mRNA molecules in proximity. A cell tagged with one or more punctate dots was classified as ‘positive’ for a given target probe. Cells were classified as: FRβ<sup>−</sup> (HBCs), CD80<sup>−</sup> (cells expressing CD80), VIM<sup>−</sup> (cells of mesenchymal origin). Composite cell classifiers were then applied to identify cells that were positive for more than one probe, including cells that were: FRβ<sup>+</sup>/CD80<sup>−</sup> (Activated/M1-like polarised HBCs), FRβ<sup>+</sup>/VIM<sup>−</sup> (HBCs of mesenchymal origin), or FRβ<sup>+</sup>/CD80<sup>−</sup>/VIM<sup>−</sup> (Activated/M1-like polarised HBCs of mesenchymal origin). The number of detections for each classifier was summed across 20 fields of view for each placental sample to obtain a total detection count for each classifier per sample. Then, for each sample, these classifiers were used to calculate the following:

\[
\text{Eq. 1. Relative level of HBCs} = \frac{\text{Number of FRβ}^+ \text{ cells}}{\text{Total number of cells detected}}
\]

\[
\text{Eq. 2. Proportion (%) of HBCs that were M1-like polarised} = \frac{\text{(Number of FRβ}^+ \times \text{CD80}^- \text{ cells)} \times \text{Number of FRβ}^+ \text{ cells}}{100}
\]

\[
\text{Eq. 3. Proportion (%) of HBCs of mesenchymal origins} = \frac{\text{(Number of FRβ}^+ \times \text{VIM}^- \text{ cells)} \times \text{Number of FRβ}^+ \text{ cells}}{100}
\]

\[
\text{Eq. 4. Proportion (%) of HBCs that were M1-like polarised and of mesenchymal origins} = \frac{\text{(Number of FRβ}^+ \times \text{CD80}^- \times \text{VIM}^- \text{ cells)} \times \text{Number of FRβ}^+ \text{ cells}}{100}
\]

From these proportions (equations 2–4), we deduced the proportion of HBCs that were M2-polarised (100 – proportion [%] of HBCs that were M1-like polarised), of non-mesenchymal origins (100 – proportion [%] of HBCs of mesenchymal origins), or both (100 – proportion [%] of HBCs that were M1-like polarised and of mesenchymal origins).

We also used the sub-cellular detection classifier in QuPath to quantify the level of FRβ expression by HBCs for each sample (i.e., the number of FRβ dots on each FRβ<sup>+</sup> cell detected across 20 fields of view), which was used to determine:

\[
\text{Eq. 5. Average FRβ expressed by HBCs} = \frac{\text{Total FRβ (spots)}}{\text{Number of FRβ}^+ \text{ cells}}
\]

A script was generated and applied to process all annotated fields of view, for each sample, using the optimised analysis settings and the batch processing function in QuPath (Supplementary Table S2 and Figure S2A-D).

**Statistical analysis**

Data were analysed using JMP (version 16.0, SAS Institute Inc, Cary, NC). Associations between study group with: 1. percent syncytium and stromal cells stained with FRα, PCFT and RFC (overall, and at low, medium, and high thresholds), and 2. HBC phenotype variables (relative level, polarisation, origins and average FRβ expression) were tested using unadjusted (ANOVA, for parametric data; Wilcoxon test, for non-parametric data) and adjusted (standard least squares regression and Tukey’s post hoc test) models. All adjusted models included infant sex (male, female; categorical) and gestational age at delivery (20–41 weeks; continuous). Data are reported as median (IQR) with p values from standard least squares regression (adjusted). Statistical significance was set at p<0.05.

To determine whether key maternal and infant characteristics may relate to placental folate transporter/receptor expression or HBC phenotype, we also explored associations between maternal pre-pregnancy BMI and reported B vitamin intake, and infant GA at delivery with HBC phenotype and placental folate transport, using Spearman’s rank correlation (rho [ρ]) test. Statistical significance was set at p<0.05.
Results

Clinical cohort characteristics
Baseline characteristics for PT controls (n=12), controls (n=10), and cases (n=12) have been previously described and the groups were highly similar. This is likely a folate replete population, given that all mothers in the case and control groups reported taking prenatal vitamins and that in Canada, fortification of white flour, enriched pasta and corn meal with folic acid is mandatory.

Placental folate transporter expression did not differ between cases and controls
FRα protein immunolabelling was largely localized to the syncytiotrophoblast, with some staining in villous core connective tissue cells and the endothelial cells of the fetal capillaries (Figure 1). A high degree of PCFT and RFC protein immunolabelling was visible in the syncytiotrophoblast and cytotrophoblast cells layers, as well as in the villous core connective tissue cells and the endothelial cells of the fetal capillaries (Figure 1). There were no differences between cases, controls and PT controls in the total percent of syncytiun and stromal cells that were positive for FRα, PCFT, or RFC protein immunolabelling (Figure 2A-B, Supplementary Table S3). There were also no differences between cases, controls and PT controls in the percent of syncytiun and stromal cells that were positive for FRα, PCFT, or RFC protein immunolabelling at the low, medium, and high staining intensity thresholds (Figure 2A-B, Supplementary Table S3).

HBC abundance and FRβ expression were increased in cases compared to PT controls
Cases had a higher proportion of placental villous cells that were HBCs (FRβ+ cells) than GA-matched PT controls (6.9% [4.3, 10.2] vs. 2.4% [1.2, 3.2], p=0.0001; Figure 3B-C, Supplementary Table S4). Average FRβ expression by HBCs, determined by the number of FRβ spots (mRNA molecules) per HBC, was also higher in cases than PT controls (3.2 mRNA molecules per HBC [2.5, 4.2] vs. 2.3 [2.1, 2.6], p=0.03; Figure 3D, Supplementary Table S4). There were no differences between cases and controls for the proportion of placental villous cells that were HBCs, or average FRβ expression by HBCs (Figure 3B-D, Supplementary Table S4).

A higher proportion of HBCs in cases were of mesenchymal origin and polarised to a regulatory (M2) phenotype, compared to controls
The proportion of HBCs that were of mesenchymal origins (VIM+) was higher in cases than PT controls (43.7% [39.8, 54.9] vs. 1.8% [0.7, 3.3], p<0.0001; Figure 3E, Supplementary Table S4). Overall, the proportion of HBCs with mesenchymal origins in PT controls was low, indicating a dominance of HBCs of non-mesenchymal origins (Figure 3B and E). There were no differences between cases and controls for the proportion of HBCs that were of mesenchymal origins (Figure 3E, Supplementary Table S4).

Cases had a lower proportion of HBCs that were polarised to an activated (M1-like) phenotype (CD80+) than PT controls overall (7.9% [2.6, 17.7] vs. 26.6% [15.8, 33.3], p=0.01; Figure 3F, Supplementary Table S4). Cases also had a lower proportion of activated (CD80+) HBCs with non-mesenchymal origins (VIM-) than PT controls (5% [0.9, 10] vs. 24.8% [15.2, 32.5], p=0.00003), but a higher proportion of activated HBCs that were of mesenchymal origins (VIM+) than PT controls (5% [0.9, 10] vs. 61% [0.22, 1.3], p=0.02; Supplementary Table S4). Conversely, the proportion of HBCs that were polarised to a regulatory (M2) phenotype (CD80-) was higher in cases than PT controls in HBCs of both mesenchymal and non-mesenchymal origins (Supplementary Table S4). HBC origins (mesenchymal and non-mesenchymal) did not appear to influence likelihood of HBC polarisation to an activated phenotype in cases (Supplementary Table S4). There were no differences between cases and controls in HBC polarisation, overall or within HBC subgroups stratified by mesenchymal and non-mesenchymal origins (Figure 3F, Supplementary Table S4).

HBC phenotype distribution (mesenchymal and non-mesenchymal origins, polarised to activated or regulatory phenotypes) is visualised in Figure 3G. Regulatory HBCs (M2; CD80-) comprised the majority of HBCs for all samples (except one PT control), and five cases had a low total proportion (<4%) of HBCs that were polarised to an activated phenotype (Figure 3G).

HBC phenotype in cases may differ by fetal sex
In exploratory analyses of folate-sensitive placental outcomes stratified by fetal sex, we found that male cases had a higher proportion of placental villous cells that were HBCs (FRβ+ cells) than male GA-matched PT controls (10% [7.8, 11.3] vs. 2.4% [1.8, 4.5], p=0.002; Table 1). Male cases also had higher average FRβ expression by HBCs (3.6 FRβ mRNA molecules per HBC [2.9, 4.6] vs. 2.3 [2.1, 2.6], p=0.01), and a higher proportion of HBCs with mesenchymal origins (VIM+; 43.7% [39.8, 54.9] vs. 1.8% [0.7, 3.3], p<0.0001) than male PT controls (Table 1). There were no differences in the proportion of HBCs that were activated (CD80+), or FRα, PCFT, and RFC protein immunolabeling in male cases compared to male PT controls, and no differences in HBC phenotype or placental folate transporter protein immunolabelling in male cases compared to male controls (Table 1). However, it should be noted that as only a small proportion of cases (4 of 12) and controls (2 of 10) were male, these findings should be interpreted with caution.

In females, the proportion of placental villous cells that were HBCs (FRβ+ cells) was associated with study group in adjusted analyses (p=0.01; Table 1), however, post-hoc testing did not reveal any differences between female cases and female controls. Female cases had a higher proportion of HBCs with mesenchymal origins (VIM+) than female PT controls (42.5% [39.8, 52.4] vs. 1.8% [0.2, 8.7], p=0.00001; Table 1). There were no differences in the average FRβ expression by HBCs, the proportion of HBCs that were activated (CD80+), or FRα, PCFT, and RFC protein immunolabelling in female cases compared to female PT controls, and no differences HBC phenotype or placental folate transporter protein immunolabelling in female cases compared to female controls (Table 1).

In male compared to female cases, male cases had a higher proportion of placental villous cells that were HBCs than female cases, but the difference did not persist after adjusting for gestational age (10% [7.8, 11.3] vs. 5.7% [3, 9.2], unadjusted p=0.04, adjusted p=0.16; Table 2). There were no other differences in HBC phenotype or placental folate transporter protein immunolabelling in male cases compared to female cases (Table 2).

GA at delivery and maternal reported folate intake associate with placental folate transporter expression
Overall, inclusive of study group, gestational age at delivery was negatively associated with the total percent of syncytiun and stromal cells that were positive for FRα protein immunolabelling (Spearman’s r= -0.34, p=0.049), but positively associated with the average FRβ expression by HBCs (r=0.48, p=0.004; Supplementary Figure S3).
Maternal reported folate intake (total dietary folate) was positively associated with the total percent of syncytium and stromal cells that were positive for PCFT protein immunolabeling ($\rho = 0.5$, $p = 0.03$; Supplementary Figure S3). There were no associations between other key maternal and infant data (maternal pre-pregnancy BMI, gestational age at delivery, birthweight z-score, and reported intakes of vitamins B6 and B12) and placental folate transporter expression or HBC phenotype in the full cohort.

Within cases, maternal reported folate intake was positively associated with the total percent of syncytium and stromal cells that were positive for RFC protein immunolabeling ($\rho = 0.67$, $p = 0.03$; Supplementary Figure S3). There were no associations between other key maternal and infant data and placental folate transporter expression or HBC phenotype among cases.

Discussion

To understand whether fetal SB may associate with alterations in placental immune cell phenotype and function or placental folate transport, we have shown for the first time that FR$\beta$ expression by HBCs is increased in fetuses with SB, and have confirmed prior findings of increased HBC levels in these cases. We also found that a higher proportion of HBCs in cases had mesenchymal origins, but a lower proportion were polarised to an activated (M1-like) phenotype, in comparison to a control group matched to cases for GA. In exploratory sex-stratified analysis, we found that male, but not female, cases had higher HBC levels and higher average FR$\beta$ expression by HBCs than GA-matched controls, while female cases had a higher proportion of HBCs with mesenchymal origins than female PT controls. Folate transporter expression in the placental syncytiotrophoblast was not altered in fetuses with SB, in a contemporary cohort from a region where folate deficiency is rare $^{37}$. Collectively, our findings suggest that fetal SB may...
Table 1. Associations between isolated spina bifida and Hofbauer cell abundance and phenotype and semi-quantitative placental folate transporter expression in male and female cases and controls.

<table>
<thead>
<tr>
<th>Positive syncytium &amp; stromal cells (%)</th>
<th>Male preterm controls (n=8)</th>
<th>Male Controls (n=2)</th>
<th>Male cases (n=4)</th>
<th>Unadjusted p value</th>
<th>Adjusted p value a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total FRα</td>
<td>42.4 (21.1, 53.3)</td>
<td>20.4 (5.77, 35.1)</td>
<td>32.6 (13.6, 34.5)</td>
<td>0.46</td>
<td>0.79</td>
</tr>
<tr>
<td>Total PCFT</td>
<td>55.2 (44.7, 62.7)</td>
<td>33.6 (23.6, 43.5)</td>
<td>43.3 (31.7, 48.3)</td>
<td>0.07</td>
<td>0.74</td>
</tr>
<tr>
<td>Total RFC</td>
<td>56.4 (27.9, 76.7)</td>
<td>47.8 (6, 89.7)</td>
<td>62.3 (56.7, 75.9)</td>
<td>0.72</td>
<td>0.68</td>
</tr>
</tbody>
</table>

Hofbauer cell phenotype variables

| % Placental cells that were HBCs (FRβ) | 2.4 (1.8, 4.5) a          | 6.7 (4.6, 8.7) ab   | 10 (7.8, 11.3) b  | 0.01              | 0.002             |
| Average FRβ mRNA molecules per HBC     | 2.3 (2.1, 2.6) a          | 3.04 (3.02, 3.1) ab | 3.6 (2.9, 4.6) b  | 0.008             | 0.01              |
| % Activated HBCs (CD80)                | 28.7 (16.3, 37.1)         | 12.2 (9.6, 14.8)    | 7.9 (4.3, 16.2)   | 0.06              | 0.07              |
| % Mesenchymal HBCs (VIM)               | 1.8 (0.8, 3.3) a          | 51.09 (51.08, 51.1) b | 52.9 (38.5, 56.4) b | 0.008             | <0.0001           |
| % Mesenchymal/activated HBCs (VIM CD80) | 0.57 (0.22, 1.34)        | 6.7 (5.6, 7.9)      | 5 (2.1, 10.2)     | 0.02              | 0.11              |
| % Mesenchymal/regulatory HBCs (VIM CD80) | 1.4 (0.3, 2) a           | 44.4 (43.2, 45.5) b | 46.2 (35.9, 48.5) b | 0.008             | <0.0001           |
| % Non-mesenchymal/activated HBCs (VIM CD80) | 28.4 (15.6, 33.3) a     | 5.5 (4, 6.9) ab    | 2.9 (2.2, 6) b    | 0.01              | 0.02              |
| % Non-mesenchymal/regulatory HBCs (VIM CD80) | 71 (58.5, 82.2)           | 43.4 (42, 44.9)    | 44 (37.8, 59)     | 0.02              | 0.12              |

Positive syncytium & stromal cells (%)

<table>
<thead>
<tr>
<th>Male preterm controls (n=4)</th>
<th>Female preterm controls (n=8)</th>
<th>Female Controls (n=8)</th>
<th>Female cases (n=8)</th>
<th>Unadjusted p value</th>
<th>Adjusted p value a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total FRα</td>
<td>18.1 (5.8, 28.1)</td>
<td>24.5 (11.6, 42.8)</td>
<td>38.9 (22.1, 50.2)</td>
<td>0.33</td>
<td>0.33</td>
</tr>
<tr>
<td>Total PCFT</td>
<td>42 (32.1, 49.9)</td>
<td>27.2 (14.1, 53.7)</td>
<td>46.8 (19.7, 64.1)</td>
<td>0.65</td>
<td>0.36</td>
</tr>
<tr>
<td>Total RFC</td>
<td>44.6 (25.2, 59.5)</td>
<td>61 (44.6, 66.8)</td>
<td>57.5 (47.9, 78.6)</td>
<td>0.36</td>
<td>0.89</td>
</tr>
</tbody>
</table>

Hofbauer cell phenotype variables

| % Placental cells that were HBCs (FRβ) | 1.9 (0.9, 3.1) a          | 8.7 (6.2, 9.8) b    | 5.7 (3.9, 2) ab   | 0.02              | 0.01              |
| Average FRβ mRNA molecules per HBC    | 2.4 (1.7, 2.7)            | 3.5 (2.8, 5.6)      | 2.8 (2.5, 4.1)    | 0.04              | 0.21              |
| % Activated HBCs (CD80)               | 21.8 (15.8, 32)           | 17.3 (8.4, 27.5)    | 7.5 (2.1, 17.8)   | 0.08              | 0.29              |
| % Mesenchymal HBCs (VIM)              | 1.8 (0.2, 8.7) a          | 34.4 (29, 37.6) b   | 42.5 (39.8, 52.4) b | 0.002             | 0.00001           |
| % Mesenchymal/activated HBCs (VIM CD80) | 0.61 (0.13, 2.8)          | 6.9 (3.2, 13.1)     | 4.3 (0.79, 10)    | 0.046             | 0.17              |
| % Mesenchymal/regulatory HBCs (VIM CD80) | 1.2 (0.06, 5.9) a         | 26.8 (24.5, 29.5) b | 40 (33.4, 41.5) b | 0.001             | 0.00001           |
| % Non-mesenchymal/activated HBCs (VIM CD80) | 20.1 (15.2, 30.7) a       | 9.7 (5.2, 14.1) ab  | 3.1 (1.6, 8.8) b  | 0.004             | 0.01              |
| % Non-mesenchymal/regulatory HBCs (VIM CD80) | 74.6 (66.1, 82.7) a       | 55.2 (46, 61.5) ab  | 55.3 (41.6, 58.6) b | 0.03              | 0.02              |

a Adjusted for gestational age at delivery.

Data are median (IQR) with p value for one-way analysis of variance (Unadjusted: ANOVA [normal distribution/equal variance] or Wilcoxon test [non-parametric data or outliers]; Adjusted: Standard least squares regression models). Groups connected by different letters are statistically different (p<0.05; Tukey’s post-hoc). FRα = folate receptor alpha. PCFT = proton coupled folate receptor. RFC = reduced folate carrier. FRβ = folate receptor beta. CD80 = cluster of differentiation 80. VIM = vimentin. HBCs = Hofbauer cells.
Figure 2. FRα, PCFT, and RFC protein staining of immunolabeled areas in placental syncytium and stromal cells. (A) Boxplots of FRα, PCFT, and RFC protein staining of immunolabeled areas in placental syncytium and stromal cells in PT controls and controls, and cases. There were no differences for total percent FRα-, PCFT-, or RFC- positive syncytium and stromal cells, or percent FRα-, PCFT- and RFC- positive syncytium and stromal cells at the low, medium, and high staining intensity thresholds, between cases, controls and PT controls. (B) Heatmap of total and low, medium, and high intensity staining of immunolabeled areas in placental syncytium and stromal cells. Data from semi-quantitative analysis of staining in immunolabeled areas were analysed using standard least squares regression models, adjusted for infant sex and gestational age at delivery. FRα = folate receptor alpha. PCFT = proton coupled folate transporter. RFC = reduced folate carrier.
Figure 3. Hofbauer cell detection and phenotype in cases, PT controls, and controls. (A) Visual schematic of the methods used to profile HBC phenotype in human placentae, and the HBC phenotypic classifiers that were considered. (B) Representative images from RNA in situ hybridization using target probes specific to human FRβ (yellow), VIM (pink), and CD80 (red), and DAPI nuclear stain (blue) on human placental villous tissue. Top panels left-to-right show probe detection in PT controls, controls, and cases. Bottom panels show a closer frame from the same samples pictured in the top panels. One dot = one mRNA molecule. Triangles = probe staining (for each respective colour). Arrowhead = syncytiotrophoblast. Cases had a higher proportion of (C) % FRβ+ cells (HBCs; pan-HBC marker), (D) average FRβ expression by HBCs, and (E) VIM+ HBCs (HBCs with mesenchymal origins) than PT controls. (F) Cases had a lower proportion of CD80+ HBCs (marker for M1-like polarised HBCs) than PT controls. (G) A stacked bar chart visualising the distribution of HBC phenotypes observed (% HBCs with mesenchymal and non-mesenchymal origins, polarised to activated or regulatory phenotypes). Pink = activated HBCs. Purple = regulatory HBCs. Bright colours = HBCs with mesenchymal origins. Faded colours = HBCs with non-mesenchymal origins. Yellow = the proportion (%) of total cells that were HBCs. Data were analysed using standard least squares regression models, adjusted for infant sex and gestational age at delivery. HBC = Hofbauer cell. FRβ = folate receptor beta. CD80 = cluster of differentiation 80. VIM = vimentin.
Table 2. Hofbauer cell abundance and phenotype and semi-quantitative placental folate transporter expression in male compared to female cases.

<table>
<thead>
<tr>
<th>Positive syncytium &amp; stromal cells (%)</th>
<th>Male cases (n=4)</th>
<th>Female cases (n=8)</th>
<th>Unadjusted p value</th>
<th>Adjusted p value a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total FRα</td>
<td>32.6 (13.6, 34.5)</td>
<td>38.9 (22.1, 50.2)</td>
<td>0.31</td>
<td>0.72</td>
</tr>
<tr>
<td>Total PCFT</td>
<td>43.3 (21.7, 48.3)</td>
<td>46.8 (19.7, 64.1)</td>
<td>0.73</td>
<td>0.81</td>
</tr>
<tr>
<td>Total RFC</td>
<td>62.3 (56.7, 75.9)</td>
<td>57.5 (47.9, 78.6)</td>
<td>0.5</td>
<td>0.69</td>
</tr>
</tbody>
</table>

Hofbauer cell phenotype variables

| % Placental cells that were HBCs (FRβ+) | 10 (7.8, 11.3) | 5.7 (3.9, 9.2) | 0.04 | 0.16 |
| Average FRβ mRNA molecules per HBC    | 3.6 (2.9, 4.6) | 2.8 (2.5, 4.1) | 0.31 | 0.79 |
| % Activated HBCs (CD80+)              | 7.9 (4.3, 16.2) | 7.5 (2.1, 17.8) | 0.87 | 0.77 |
| % Mesenchymal HBCs (VIM+)             | 52.9 (38.5, 56.4) | 42.5 (39.8, 52.4) | 0.4 | 0.21 |

| % Mesenchymal/activated HBCs (VIM+/CD80+) | 5 (2.1, 10.2) | 4.3 (0.8, 10) | 0.73 | 0.98 |
| % Mesenchymal/regulatory HBCs (VIM+/CD80+) | 46.2 (35.9, 48.5) | 39.8 (33.4, 41.5) | 0.09 | 0.08 |
| % Non-mesenchymal/activated HBCs (VIM+/CD80+) | 2.9 (2.2, 6) | 3.1 (1.6, 8.8) | 0.73 | 0.5 |
| % Non-mesenchymal/regulatory HBCs (VIM+/CD80+) | 44.1 (37.8, 59) | 55.3 (41.6, 58.6) | 0.5 | 0.38 |

a Adjusted for gestational age at delivery.

Data are median (IQR) with p value for one-way analysis of variance (Unadjusted: Wilcoxon test; Adjusted: Standard least squares regression models). FRα = folate receptor alpha. PCFT = proton coupled folate receptor. RFC = reduced folate carrier. FRβ = folate receptor beta. CD80 = cluster of differentiation 80. VIM = vimentin. HBCs = Hofbauer cells.

associate with an increase in HBC proliferation and function, which could be a mechanism contributing to placental villous maldevelopment observed in these fetuses12,17 and provide further evidence in support of a role for immune dysregulation in NTDs38.

Our finding that cases had a higher proportion of cells that expressed FRβ (a marker for HBCs38), compared to GA-matched controls, may suggest an increase in HBC proliferation in cases. HBC proliferation has been reported in pregnancy pathologies associated with immune activation, brought about by infectious agents or immune-mediated processes39. As immune dysregulation is one known contributor to the pathogenesis of NTDs, and in particular, folate-resistant NTDs38, we hypothesised that HBC proliferation in cases may be a placental marker for an altered immune phenotype in the uterine environment. Indeed, the increase in HBC number in cases is consistent with findings from placental histopathology assessments in this cohort17 and a historical cohort12, and appears to be driven by a largely M2-polarised HBC population, which play important regulatory roles in placental immunomodulation34,40. Cases also had increased FRβ expression by HBCs, which may be an adaptive response to a villous microenvironment that is more ‘competitive’ for folate resources, due to the high number of HBCs, or be required for an increase in HBC function. Further, we previously reported that cases in this cohort had upregulated expression of five genes known to be expressed by HBCs, including genes involved in inflammatory response regulation, which is consistent with an overall enhancement of HBC function in cases22. Given that HBCs regulate placental angiogenesis, and changes in HBC number or polarisation may alter angiogenesis34, an altered HBC phenotype may contribute to placental villous maldevelopment observed in these cases37. Future studies should consider a deeper phenotyping of the role of regulatory (M2) HBC subtypes (M2a, M2b, M2c, and M2d40) in placental physiology in both healthy fetuses, and those with isolated SB, to better delineate how HBC composition may relate to placental villous maldevelopment in fetuses with isolated NTDs.

Cases also had a higher proportion of HBCs that were of mesenchymal origins than PT controls. While HBC ontogeny across pregnancy is not well understood, as gestation progresses, fetal monocyte-derived macrophages are proposed to gradually replace the population of HBCs that arose from villous mesenchymal stem cells earlier in pregnancy15,16. The proportion of HBCs expressing VIM in PT controls, specifically, was low, which could suggest a relative increase in fetal monocyte-derived macrophages in the PT control group. It is possible that the PT controls themselves had placental dysfunction, given the role of placental maldevelopment in PT birth8, and notably, placental lesions have been shown to associate with fetal monocyte and monocyte subset phenotypes in fetuses born PT41. However, HBC polarisation was not influenced by whether HBCs were derived from mesenchymal or non-mesenchymal tissues in any of the study groups. Thus, it remains unclear whether the differences in HBC origins between study groups may relate to placental phenotype more broadly, and this is an area requiring further investigation.

We also found that male, but not female, cases had higher HBC levels and higher average FRβ expression by HBCs than male PT controls, which may suggest that male fetuses with SB have an increased susceptibility to immune-related alterations in placental phenotype. There are known sex differences in HBC gene expression/function and response to inflammatory stimuli12,42, and it is possible that altered HBC phenotypes in cases may have sex-specific effects on placental development and function42. While there were no differences in HBC phenotype between male and female cases after adjusting for GA, the number of male cases in this cohort was small and larger studies are needed to further explore sex-stratified and -interacting relationships between fetal SB and HBC phenotype. An improved understanding of whether placental immune function differs between male and female cases could provide insight into sex-specific NTD phenotypes and should be a focus for future research.

Because folate deficiency is a well-established risk factor for NTDs1-3 and may contribute to poor fetal growth5, we hypothesised that cases
would have reduced expression of placental folate transporters, which may associate with suboptimal fetal growth. Contrary to our hypothesis, we found no differences in semi-quantitative assessments of placental folate transporter protein localisation or expression (for FRα, PCFT, and RFC) across study groups, and no associations between placental folate transporter expression and birthweight. Our findings are inconsistent with previous studies from India and Mexico, which have reported upregulated FRα and RFC expression in placenta from fetuses with NTDs, and upregulated PCFT expression in placentae from fetuses with congenital anomalies (including, but not limited to, NTDs). India does not have mandatory folic acid fortification and folic acid fortification in Mexico is not well enforced, suggesting that suboptimal maternal folate status may have contributed to the changes observed in placental folate transport in these studies. However, it is likely that the SB cases in this cohort were not folate-responsive NTDs, given that folate deficiency is rare in the region the study took place and that all mothers in the cohort were taking prenatal vitamins. The lack of differences in folate transporter immunolabelling reported here are consistent with transcript-level data for expression of FRα, PCFT, and RFC we have reported previously for this cohort. It is possible that the suboptimal growth observed in ~50% of the cases in this cohort was, in part, driven by dysfunction in other nutrient-related placental processes, such as lipid metabolism and amino acid transport, and this is an area requiring further study.

Our use of automated analysis pipelines in QuPath to characterise placental histological features through IHC and ISH is a key strength of our study. IHC results are typically interpreted using visual semi-quantitative assessments, which can be influenced by the experience-level of the assessor and have limitations for accuracy and reproducibility. Further, the use of QuPath allowed us to evaluate average marker expression over more frames of placental tissue than are typically feasible when performing assessments manually. Future studies should consider measuring maternal folate levels to investigate relationships between maternal folate status and placental folate transport in fetuses with SB. Characterising HBC subtypes (e.g., M2a, M2b, M2c, and M2d, each of which differ in function, surface marker expression, and cytokine secretions) would also improve our understanding of how HBC phenotype may be altered in fetuses with isolated NTDs.

This study is the first to characterise HBC phenotypes in fetuses with SB, and the first to evaluate placental folate transport in a cohort of fetuses with isolated SB in Canada. Understanding how HBC phenotypes are altered in fetuses with SB helps to increase knowledge on the immune-related factors that may contribute to NTD pathogenesis, phenotype, and NTD-associated comorbidities. That placental folate transport in cases did not differ from fetuses without congenital anomalies is promising, but affirms the need for ongoing research to better delineate the folate-independent mechanisms that continue to drive fetal NTDs and associated comorbidities.

Acknowledgements

The authors would like to thank Vagisha Pruthi for overseeing the study recruitment, data entry and sample collection, the staff at the Research Centre for Women’s and Infants’ Health (RCWIH) BioBank for collecting and processing the placental samples, and the staff at the Louise Pelletier Histology Core Facility and the Cell Biology and Image Acquisition Core Facility for their assistance with slide imaging.

This research is supported by the Canadian Institutes of Health Research (CIHR PJT-175161) and departmental research grants from the Department of Obstetrics and Gynaecology at Mount Sinai Hospital, Toronto, and the Department of Health Sciences at Carleton University, Ottawa. MW was supported by an Ontario Graduate Scholarship, Faculty of Science, Carleton University.

Conflicts of interest

All authors declare no conflicts of interest.

Author contributions

Conceptualization: MW, KLC, TVM, and DG; Resources: TVM and KLC; Investigation: MW, KLC, HA, DG; Data curation: MW and HA; Methodology: MW, KLC, HA; Formal analysis: MW and HA; Visualization: MW; Writing – original draft preparation: MW and KLC; Writing – reviewing & editing: MW, KLC, TVM, HA, and DG. Funding acquisition: KLC and TVM; Supervision: KLC.

Ethics

This study was approved by the Carleton University Research Ethics Board (108884 and 106932) and the Mount Sinai Hospital Research Ethics Board (17-0028E and 17-0186-E).

References


White et al. [medRxiv] Nov 23, 2023 |
and ACD

Joerink M, Rindsjö E, van Riel B, Alm J, Papadogiannakis N. Placental Reproduction and M2c polarization may regulate feto...


